Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotevtamab in advanced solid malignancy
NCT02412462Phase 1Completed
- Sponsor
- Alethia Biotherapeutics
- Start
- Apr 2015
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotevtamab in solid tumor, sponsored by Alethia Biotherapeutics. Primary endpoint: Number of participants with an adverse event as a measure of safety and tolerability. Started Apr 2015; status: completed.
02
Drugs
sotevtamab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02412462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412462.